1. Home
  2. LYRA vs FEBO Comparison

LYRA vs FEBO Comparison

Compare LYRA & FEBO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LYRA
  • FEBO
  • Stock Information
  • Founded
  • LYRA 2005
  • FEBO 1993
  • Country
  • LYRA United States
  • FEBO Hong Kong
  • Employees
  • LYRA N/A
  • FEBO N/A
  • Industry
  • LYRA Medical/Dental Instruments
  • FEBO
  • Sector
  • LYRA Health Care
  • FEBO
  • Exchange
  • LYRA Nasdaq
  • FEBO Nasdaq
  • Market Cap
  • LYRA 13.5M
  • FEBO 14.0M
  • IPO Year
  • LYRA 2020
  • FEBO 2023
  • Fundamental
  • Price
  • LYRA $0.21
  • FEBO $1.27
  • Analyst Decision
  • LYRA Buy
  • FEBO
  • Analyst Count
  • LYRA 5
  • FEBO 0
  • Target Price
  • LYRA $4.50
  • FEBO N/A
  • AVG Volume (30 Days)
  • LYRA 907.8K
  • FEBO 8.4K
  • Earning Date
  • LYRA 03-20-2025
  • FEBO 10-03-2024
  • Dividend Yield
  • LYRA N/A
  • FEBO N/A
  • EPS Growth
  • LYRA N/A
  • FEBO N/A
  • EPS
  • LYRA N/A
  • FEBO N/A
  • Revenue
  • LYRA $1,471,000.00
  • FEBO $16,319,897.00
  • Revenue This Year
  • LYRA N/A
  • FEBO N/A
  • Revenue Next Year
  • LYRA N/A
  • FEBO N/A
  • P/E Ratio
  • LYRA N/A
  • FEBO N/A
  • Revenue Growth
  • LYRA 3.37
  • FEBO 9.01
  • 52 Week Low
  • LYRA $0.16
  • FEBO $1.20
  • 52 Week High
  • LYRA $6.79
  • FEBO $17.68
  • Technical
  • Relative Strength Index (RSI)
  • LYRA 57.63
  • FEBO 38.48
  • Support Level
  • LYRA $0.19
  • FEBO $1.20
  • Resistance Level
  • LYRA $0.22
  • FEBO $1.39
  • Average True Range (ATR)
  • LYRA 0.01
  • FEBO 0.09
  • MACD
  • LYRA 0.00
  • FEBO 0.01
  • Stochastic Oscillator
  • LYRA 66.75
  • FEBO 24.22

About LYRA Lyra Therapeutics Inc.

Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.

About FEBO Fenbo Holdings Limited

Fenbo Holdings Ltd is a company engaged in producing premium personal care electric appliances principally electrical hair styling products such as straighteners, curlers, trimmers, etc., and toy products to overseas markets. It manufactures and sells products such as Straightener, Mini Straightener, and Curling Iron.

Share on Social Networks: